Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Search Videos by Topic or Participant
Browse by Series:

TKIs in Philadelphia Chromosome-Positive ALL

Panelists: Dan Douer, MD, MSK; Richard M. Harris, MD, Cedars Sinai; Jeffrey Lancet, MD, Moffitt; Mark R. Litzow, MD, Mayo Clinic; Leonard S. Sender
Published: Wednesday, Feb 18, 2015
For High-Definition, Click
The introduction of tyrosine kinase inhibitors (TKIs), like imatinib, for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized outcomes in younger patients and created an opportunity for more definitive therapy in older individuals, according to Jeffrey Lancet, MD. Lancet notes that several smaller series of studies have demonstrated high response rates and significant disease-free survival rates in individuals who received TKIs with modified chemotherapeutic regimens or steroids.

Dan Douer, MD, and Mark R. Litzow, MD, agree that adults with Ph+ ALL should undergo allogeneic stem cell transplant following treatment with TKIs. In many instances, the level of response induced by targeted therapies lends itself to better outcomes from transplant. However, whether imatinib should be administered following transplantation remains an area of debate.
Slider Left
Slider Right
For High-Definition, Click
The introduction of tyrosine kinase inhibitors (TKIs), like imatinib, for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized outcomes in younger patients and created an opportunity for more definitive therapy in older individuals, according to Jeffrey Lancet, MD. Lancet notes that several smaller series of studies have demonstrated high response rates and significant disease-free survival rates in individuals who received TKIs with modified chemotherapeutic regimens or steroids.

Dan Douer, MD, and Mark R. Litzow, MD, agree that adults with Ph+ ALL should undergo allogeneic stem cell transplant following treatment with TKIs. In many instances, the level of response induced by targeted therapies lends itself to better outcomes from transplant. However, whether imatinib should be administered following transplantation remains an area of debate.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Publication Bottom Border
Border Publication
x